Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Condition:   HER2-positive Breast Cancer Intervention:   Drug: trastuzumab deruxtecan (T-DXd) (IV) Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials